Becton Dickinson Pledges $19 Bn US Investment, Earmarks $3 Bn for Manufacturing

The agreement has also tied Becton Dickinson’s US manufacturing commitments to potential relief from future Section 232 tariffs on covered products and inputs.

Becton Dickinson has committed $19 Bn in US investment over several years, with $3 Bn allocated to manufacturing expansion amid the US government’s push to bring more healthcare production within the country.

The agreement has also tied Becton Dickinson’s US manufacturing commitments to potential relief from future Section 232 tariffs on covered products and inputs. The tariff relief will depend on the final scope and timing of the measures, as well as the company meeting agreed milestones.

"This agreement reflects a shared commitment between the U.S. Government and BD to strengthening America's healthcare infrastructure, expanding U.S. manufacturing capacity and supporting reliable access to essential medical technologies, ultimately building a more resilient healthcare system for the future," said Tom Polen, BD’s CEO.

The company has said the investment will allow it to increase US production by around 5 Bn essential medical consumables annually, raising the proportion of such products supplied domestically to roughly 80%.

Becton Dickinson has also committed to producing all needles required for use in the US domestically, using American-made steel.

However, the company has not yet quantified the financial impact of the agreement, citing uncertainty around final tariff rates, product coverage and implementation timelines.

The $3 Bn manufacturing commitment builds on investments already being made by Becton Dickinson in the US.

In January, the company announced a $110 Mn expansion in Columbus, Nebraska, focused on prefillable syringe and cannula production, with syringe production scheduled to begin supplying customers in mid-2026.

Becton Dickinson operates manufacturing facilities across several US locations, including Nebraska, Connecticut, Texas, Georgia, Utah, and South Carolina, as well as Puerto Rico.

Its portfolio includes medical devices and consumables such as syringes, catheters, endoscope systems, and other products used across healthcare settings.

Becton Dickinson said the agreement provides greater long-term certainty for manufacturing and supply chain planning, while further details will be provided once the Section 232 tariffs are finalized.

Stay tuned for more such updates on Digital Health News